華聞集團(000793.SZ)董事會通過關於授權辦理中期票據有關事項
格隆匯 9 月 29日丨華聞集團(000793.SZ)公佈,公司第八屆董事會2020年第十三次臨時會議決議,審議並通過《關於授權辦理中期票據有關事項的議案》。
公司2017年度第一期中期票據10億元將於2020年11月8日到期,2018年度第一期中期票據13億元將於2021年4月4日到期。
同意提請公司股東大會授權公司經營班子負責辦理存續的中期票據有關事項,包括但不限於兑付、展期、增信、置換、資金管理等事宜,並簽署相關協議文件及其補充協議、辦理相關手續等。
該議案尚需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.